Cure8 research brief
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares earlier or reduce reliance on stool collection and blood draws.
Adult patients with Crohn's disease or ulcerative colitis who track inflammation, gastroenterologists and IBD nurses, and researchers working on wearable biomarkers and inflammation monitoring.
The researchers enrolled 33 patients with IBD (Crohn's disease and ulcerative colitis) and collected continuous on-body perspiration measurements for 40–130 minutes while synchronously obtaining serum CRP and, for a subcohort, fecal calprotectin.
The paper reports that perspiration CRP and calprotectin measurements were consistent with corresponding serum and stool measurements and that marker patterns differed by diagnosis (CRP higher in CD; calprotectin higher in UC) and disease location (colonic IBD showing higher calprotectin).
The work is presented as a cross-sectional clinical study showing feasibility and correlation over short monitoring periods, not as proof that wearable monitoring changes clinical outcomes. Larger studies and longer-term testing would be needed before this could replace standard blood or stool testing.
The study is cross-sectional with 33 participants and short monitoring sessions (40–130 minutes). Findings show correlation with serum and stool markers but do not demonstrate improved clinical outcomes or long-term reliability; further validation in larger, longer studies is needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
